Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD

Key Points

• Empowered Funds purchased 48,982 ACADIA Pharmaceuticals shares during the first quarter, valued at approximately $1.09 million. Institutional investors and hedge funds own 96.71% of the company.
• ACADIA reported quarterly EPS of $0.18, beating the $0.07 consensus estimate, while revenue reached $308 million and rose 16.4% year over year.
• Analyst sentiment remains broadly positive, with 14 Buy ratings and three Holds producing a “Moderate Buy” consensus and an average price target of $33.44; however, insiders have sold 42,100 shares over the past three months.

Empowered Funds LLC purchased a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 48,982 shares of the biopharmaceutical company's stock, valued at approximately $1,090,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. State Street Corp grew its holdings in ACADIA Pharmaceuticals by 9.0% during the 4th quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company's stock worth $211,296,000 after acquiring an additional 655,257 shares during the last quarter. First Trust Advisors LP raised its stake in shares of ACADIA Pharmaceuticals by 47.3% in the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company's stock worth $74,435,000 after acquiring an additional 1,073,834 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of ACADIA Pharmaceuticals by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,239,451 shares of the biopharmaceutical company's stock worth $86,539,000 after purchasing an additional 106,807 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ACADIA Pharmaceuticals by 8.0% during the first quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company's stock worth $70,222,000 after purchasing an additional 234,186 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of ACADIA Pharmaceuticals by 19.8% during the third quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company's stock valued at $50,339,000 after purchasing an additional 389,170 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $29.21 on Friday. The stock has a market cap of $5.03 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 17.19 and a beta of 0.81. The stock has a 50-day moving average of $24.39 and a 200-day moving average of $23.27. ACADIA Pharmaceuticals Inc. has a one year low of $19.69 and a one year high of $29.48.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. ACADIA Pharmaceuticals's quarterly revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.16 EPS. As a group, research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider directly owned 24,509 shares of the company's stock, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares in the company, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 42,100 shares of company stock worth $1,134,287. Company insiders own 26.20% of the company's stock.

Wall Street Analyst Weigh In

ACAD has been the subject of several research analyst reports. Royal Bank Of Canada boosted their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the stock an "outperform" rating in a research report on Wednesday. Weiss Ratings reiterated a "hold (c)" rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a "hold" rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Bank of America reaffirmed a "buy" rating and set a $14.50 price target on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $33.44.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source